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Summary 
Evidence-based guidance for national infection prevention and control (IPC) programmes is 
needed to support national and global capacity building to reduce  healthcare-associated 
infection and antimicrobial resistance. This systematic review evaluated the evidence on the 
effectiveness of  IPC interventions implemented at national or sub-national level to inform 
the development of World Health Organization’s guidelines on the core components of 
national IPC programmes. CENTRAL, CINAHL, EMBASE, MEDLINE, and WHO IRIS were 
searched from January 1, 2000 to April 19, 2017. Twenty-nine studies meeting the eligibility 
criteria were categorised according to  intervention type: multimodal; care bundles; policies; 
and surveillance, monitoring, and feedback. There was evidence of effectiveness in all 
categories but the best quality evidence  was on multimodal interventions and surveillance, 
monitoring, and feedback. We call for improvements in study design, reporting of research 
and robust evidence, in particular from low income countries, to strengthen the uptake and 
international relevance of IPC interventions. 
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Panel: Recommendations and future research  
 This review of the effectiveness of  IPC interventions based on international, 
national, state or collaborative guidelines and implemented countrywide, region 
wide or across countries, regions or collaborations was undertaken to inform the 
development of international guidance on national IPC programmes. 
 Surveillance with active feedback tended to report positive effects, as did the 
majority of multimodal interventions.  
 There is some evidence of effectiveness for two other interventions, namely, care 
bundles and  policies.  
 No  evidence meeting the review selection criteria was found for other core 
components of IPC programmes, until this evidence becomes available, these other 
components continue to be considered “best practice” based on expert opinion 
alone. 
 Recommendations are made for improvement in future research design to ensure 
such studies develop a viable evidence base.  
 There is a need for improved research design, with cluster randomised trials (CRT), 
better designed epidemiology studies including rigorous time series analysis, and the 
consistent use of standardised outcomes to inform the future evidence base for IPC. 
 In addition, it is important to measure both outcomes and processes, particularly if 
an experimental design is not possible. 
 With regard to the reporting of studies, care should be taken to report the 
intervention content, how it was implemented, and its hypothesised mechanisms of 
action.  
 Studies also need to specify any theoretical underpinning and consider wider use of 
theory. 
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Introduction 
Healthcare-associated infection (HAI) is a major global health problem. It affects millions of 
patients worldwide every year.1,2 HAI has serious implications for patients and health care 
systems.1 A large burden of HAI exists worldwide, despite a call to action over the last 
decade to make care safer.3 Estimates suggest 80,000 patients/per day have at least one 
HAI on any given day in Europe, corresponding to a prevalence of 5·7% of hospitalized 
patients (95% confidence interval (CI): 4·5% to 7·4%) suffering from HAI.4 The estimated HAI 
prevalence  in low-income countries ranges from 5·7% to 19·1%.1  
 
The contribution of antimicrobial resistance (AMR) to HAI at a global level is not well 
described. However, it is known that wide national variations in multidrug resistance exist, 
with low resistance rates in some countries, particularly in Northern Europe, and alarming 
prevalence in others. Extended-Spectrum β-Lactamase-producing Escherichia coli and 
Klebsiella spp range in terms of the proportion of isolates which are resistant, from 11·8% to 
58·5% and from 35·1% to 57·3%, respectively, and for Meticillin-Resistant Staphylococcus 
aureus (MRSA) from 27·7% to 44·4%.
5 Since AMR moves freely across national borders, co-
ordinated global action is needed to maximise prevention of HAI and containment of AMR. 
Infection Prevention and Control (IPC) is recognised as a key strategy in this regard,6 with 
the focus being on what are the core components that should be part of any IPC programme, 
resulting in repeated international calls for evidence-based guidelines for core national 
interventions.1,7  
 
A recent systematic review of IPC programmes, organisation, management, and structure 
identified ten core components to reduce HAI at a hospital level,8 but no review exists on 
the components required for effective national IPC interventions. Previous World Health 
Organization (WHO) guidance on national IPC core components9 was based only on expert 
opinion. New evidence-based guidelines, including recommendations for core components of 
effective IPC programmes at the national and healthcare facility level have been developed 
by a panel of international experts to support the global prevention of HAI and reduce the 
burden of AMR. These guidelines were based on the available evidence and its quality, the 
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balance between benefits and harms, cost and resource implications, acceptability and 
feasibility, and user and patient values and preferences.10-11 Where studies not meeting our  
inclusion criteria were not available, the panel of international experts deemed it crucial to 
make best practice statements on key core components to be recommended at the national 
level. In this systematic review, as part of the guideline development, we aimed to evaluate 
the evidence on the effectiveness of IPC interventions at the national level. 
 
Methods 
This systematic review was conducted according to a protocol (appendix, page 3) and is 
reported according to the PRISMA guidelines.12  
 
Search strategy and study selection 
Inclusion criteria: studies were included in the review if they were published from 2000 to 
2016; reported in English, French, or Spanish with an English title or abstract; a population 
of healthcare workers; and an  IPC intervention, based on international, national, state or 
guidelines from a collaboration/network of hospitals,  and implemented in healthcare 
settings country-wide, region-wide or across a country, region or collaboration/network of 
hospitals. Primary outcomes were HAI rates, including those caused by antibiotic-resistant 
microorganisms, mortality, quality adjusted life years (QALY), disability adjusted life years, 
length of stay, or economic costs associated with HAI. Secondary outcomes included use of 
alcohol-based hand rub (ABHR), compliance with IPC practices (e.g. hand hygiene (HH)) and 
policies (e.g. mandatory reporting of HAI), knowledge, or attitudes. Only studies meeting 
EPOC study design criteria were included.13–15 These included full or partial economic 
evaluations, cluster randomised trials (CRT), non-randomised trials, (NRT), controlled before 
and after (CBA) studies, and interrupted time series (ITS) studies.  
 
Exclusion criteria were: locally led hospital-level interventions; interventions for the 
prevention of HAI in the context of occupational health and antibiotic stewardship; non-
controlled before and after studies; cohort studies; cross sectional surveys; reviews; letters; 
notes; conference proceedings; theses; and opinion articles.  
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Databases searched included: CENTRAL, CINAHL (via EBSCO), EMBASE (via Ovid), MEDLINE 
(via EBSCO), and the WHO IRIS. In addition, manual searching of the reference lists of the 
included studies was conducted. Consistent with the principle of using current evidence to 
inform practice and taking cognisance of the evolving nature of IPC practice, the search to 
inform the WHO guideline development included studies published from January 1, 2000 to 
December 31, 2016. The search was re-run prior to the manuscript submission and included 
studies up until April 19, 2017. This additional search added four more studies to the review. 
Delimiters were population (human only) and publication type (CINAHL and MEDLINE - 
journal article; EMBASE - article; WHO IRIS - analytic, e-journal, periodical). The database-
specific search strategy comprised both index terms and free text words; details of which 
are available in the appendix, page 8. 
 
Studies were selected in the following manner: Titles and abstracts of papers were 
individually screened against eligibility criteria by one of a team of reviewers, with 30% of 
these independently screened by a second reviewer (LP, JM, LM, DW). Full text review was 
conducted on papers by one reviewer (LP), with checking by a second reviewer (JM). 
Disagreement between reviewers was resolved by discussion or by a third reviewer (JR). 
 
Data analysis 
Data were extracted: (appendix, page 23) by two independent reviewers for 30% of the 
studies. The remaining studies were data extracted by one reviewer and checked by a 
second reviewer (LP, EC, KC, PF, TH, JM, LM, VN, JR). Disagreement between reviewers was 
resolved by discussion or by a third reviewer (LP, JM).  
 
Quality assessment: Risk of bias of individual CRT, NRT, CBA studies, and ITS studies were 
assessed using standard EPOC risk of bias criteria,16 resulting in a summary assessment of 
overall high, low or unclear risk of bias.17 Risk of bias assessments were conducted by two 
independent reviewers for 20% of the studies and by one reviewer, checked by a second 
reviewer, for the remainder of the studies (LP, JM, TH, PF, KC, EC, VN, JR). Disagreement 
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between reviewers was resolved by discussion or by a third reviewer (LP, JM). The Grades of 
Recommendation, Assessment, Development, and Evaluation (GRADE) system18–20 was used 
to grade the quality of the body of evidence, where one existed (LP, JM). Two independent 
reviewers (SM, AM, JR) used the Phillips’ checklist21 to critically appraise the methodological 
quality of each economic study.22 Disagreement between reviewers was resolved by 
discussion or by a third reviewer (LP). A narrative summary was produced in line with 
Cochrane recommendations (LP, JM, SM).23  
 
Studies were considered for meta-analysis; however, due to heterogeneity in interventions 
and primary outcomes, no meta-analysis was conducted as it was considered statistically 
inappropriate. Therefore, results were synthesised in a narrative form according to the type 
of  IPC intervention being evaluated.  
 
Results 
The database searches identified 9,960 studies. A further 139 studies were identified by 
manually searching the reference lists of included studies, resulting in 9,777 studies after 
removing duplicates, all of which were screened against the eligibility criteria. The majority 
of these (9,422) were excluded at the title/abstract screening stage, with a further 326 
excluded at full-text review. Twenty-nine studies24–53 meeting the inclusion criteria were 
included in the systematic review (figure 1, table 1).  
 
Studies were from the USA (18),26–29,32,36–38,40–47,49,50,53 England (3),24,34,51 Australia (2),35,39 
Hong Kong (2),25,30 Brazil (1),31 Israel (1),48 England and Wales (1),52 and Germany (1).33  
These included nine ITS studies,32–34,42–48 nine CRT,25–31,52,53 five CBA studies,38–41,49 one 
NRT,24 and five economic evaluations.35–37,50,51 Two studies utilised international guidelines 
from the World Health Organization25,30 and 23 national24,27-29,31,33-38,40,42-53 three 
collaborative26,32,41 and one state39 guidelines. Nine of the studies implemented the 
intervention country-wide24,35,37,41,45,47-48,50,51,52, three region- or state-wide34,38,39, seven 
across countries25,30,31,33,36,46,49, five across collaborations of hospitals27,32,42-44,53 and four 
across states. 26,28,29,40 Even though time limits for inclusion were 2000-2017, the majority of 
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the studies were recent, with 26 published between 2009 and 2017. There were several 
possible ways of categorising the studies for analysis. These included per type of infection, 
organism, or intervention. Not all studies fitted into one category so a combination of 
approaches was used. Since the findings were to be used to inform guidance on the core 
components of national IPC programmes, type of intervention was the main category with 
sub-categories according to organism or type of infection where possible.  
  
The 29 included studies were categorised into four groups:  multimodal IPC interventions (n 
= 18 studies, 418 intensive care units (ICUs), 337 hospitals, 50 long term care facilities 
(LTCFs), and 18 area health services)24–41; IPC care bundles (n = 3 studies, 32 paediatric units, 
29 ICUs and 20 hospitals)42–45; IPC policies (n = 6 studies, 2,444 hospitals)46–51; and IPC 
surveillance, monitoring and feedback (n = 2 studies, 16 area health services and eight 
hospitals).52-53 Multimodal interventions aim to improve an outcome and change behaviour 
through implementation of several elements, most commonly system change, staff 
education, monitoring and feedback, reminders, and culture change.54 Implementation uses 
an integrated and multidisciplinary approach and can be supported by practical tools, 
including care bundles and checklists. Care bundles comprise a small, straightforward set of 
evidence-based patient focused practices (generally three to five) that improve patient 
outcomes when performed collectively and reliably.54 Care bundles were differentiated 
from multimodal interventions as they are an implementation tool to guide the delivery of a 
specific aspect of a patient’s care, whereas multimodal interventions generally operate at 
the level of the organisation to change healthcare workers behaviour through 
implementation of the abovementioned elements and may include the use of care 
bundles.54 This categorisation is used to structure the results and discussion. 
 
Of the 18 studies investigating multimodal IPC strategies, there was one NRT,24 seven 
CRT,25–31 three ITS studies,32–34 three economic evaluations,35–37 and four CBA studies.38–41 
Most of the studies were conducted in acute hospital settings, but four were in LTCFs (table 
1).25,26,28,30 
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The multimodal interventions in this review varied in terms of number (ranging from two to 
eight) and type of components included (appendix, page 24), but were reported by authors 
as a collective whole with no attempts to distinguish the relative effect of the different 
elements. The most frequently cited elements were the implementation of a care bundle 
(11/18), with provision of training (12/18) and posters/campaign materials (6/18) to support 
the intervention. The target of these interventions also varied, with some aiming at 
preventing specific types of HAI, others HAIs in general,26,41 and others focusing on hand 
hygiene (HH).25,29,30,35,39 The specific infections addressed were MRSA,32,34 central line 
associated blood stream infection (CLABSI),24,27,33,36 surgical site infection (SSI),40 Clostridium 
difficile infection (CDI),37 catheter-associated urinary tract infection (CAUTI) and multidrug 
resistant organisms.28 Two studies31,38 targeted both CLABSI and ventilated-associated 
pneumonia (VAP). Outcomes were measures of infection, cost effectiveness, or compliance 
with infection control practices. All multimodal intervention studies except three26,31,40 
showed a significant effect on at least one outcome measure. The economic evaluations of 
multimodal interventions demonstrated cost savings or cost effectiveness (table 2).35–37 
 
Only four studies within the multimodal IPC interventions category measured the same 
outcome; CLABSI incidence rates per 1,000 patient or central line-days (CL-days). 24,27,31,33 
They all used Centers for Disease Control definitions, although one of these24 also used 
‘refined’ European Centre for Disease Prevention and Control definitions, therefore 
affecting case ascertainment, but not internal consistency. The other 14 studies reported a 
range of outcome measures, preventing direct comparison. 
 
Three studies, all with an ITS design and conducted in a hospital setting, investigated the 
effectiveness of patient-focused care bundles (table 1).42–45 The patient population for two 
of these studies were children, with one study43/44 taking place in ICUs and the other42 
conducted in haematology/oncology inpatient units. Miller et al43/44 describe the same 
study, which involved the introduction of insertion and maintenance care bundles for 
CLABSI, but with one year outcomes reported in 2010 and three year outcomes reported in 
2011. Bundy et al42 also implemented a CLABSI care bundle but the intervention in this 
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study was  catheter maintenance only. Both studies42,43/44 assessed the impact on CLABSI 
rates per 1,000 line days and found a significant reduction. The third study45 included a SSI 
care bundle for adults undergoing cardiac or orthopaedic surgery with MRSA SSI per 10,000 
operations as the primary outcome. The rate of MRSA SSI significantly decreased for both 
orthopaedic and cardiac operations (table 2). 
 
Six studies examined the effectiveness of a IPC policy (table 1); three used an ITS design,46–48 
one used a CBA design,49 and two were economic evaluations.50,51 The settings for all six 
studies46–51 were hospitals, although one study49 was conducted only in ICUs. The IPC 
policies involved the use of financial disincentives with non-payment for preventable 
infection in hospitals in the USA,46,47 mandatory public reporting of CLABSI infection rates in 
some USA states,49 estimated costs associated with HAI if health care antiseptic products 
were unavailable,50 cost effectiveness of MRSA screening,51 and the instigation of a infection 
control task force to contain a country-wide outbreak of carbapenem-resistant Klebsiella 
pneumoniae in Israeli hospitals.48 Neither study that evaluated non-payment for 
preventable infection46,47 showed a significant reduction in HAI, but the use of antiseptics 
was associated with hospital costs avoided50 and MRSA screening for high risk specialities 
was shown to be cost effective in terms of QALY.51 The task force48 and mandatory public 
reporting49 studies demonstrated significant reductions in HAI (table 2).  
 
Two CRT explored the effectiveness of implementing feedback of IPC practice  (table 1).52,53 
One53 was conducted in ICUs whereas the other52 in acute care settings for elderly patients, 
general medical wards and ICUs. The former53 investigated the effect of local feedback of 
infection rates combined with comparison to national data, versus feedback of local 
infection rates only; significant differences between the two groups were observed for 
CAUTI, CLABSI, VAP, and overall device-associated infection. The latter52 investigated the 
effect of providing feedback on HH compliance to individual healthcare workers and showed 
that HH compliance significantly increased (table 2).  
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Quality assessment of the 29 studies (appendix, pages 26 and 27) showed that five CRT were 
at low risk of bias,27,28,31 one with regard to its primary outcome52 and another with regard 
to its secondary outcome.25 Three other CRT29,53 had an unclear risk of bias, one concerning 
its secondary outcome.52 One ITS was also at unclear risk of bias,33 while 17 studies were at 
high risk of bias,24,26,30,32,34,38–49 one in relation to its primary outcome.25 The remaining five 
studies were economic evaluations35–37,50,51; a narrative summary of the methodological 
quality of these is available in the appendix, page 28. 
 
GRADE was applicable to assess the quality of the body of evidence for studies assessing 
multimodal IPC interventions and IPC care bundles as these were the only types of 
interventions in which the same outcomes were reported in more than one study. 
 
For multimodal IPC interventions, CLABSI incidence rate per 1,000 patient or line days was 
reported in four studies.24,27,31,33 The risk of bias for two studies27,31 indicated that there was 
an overall low risk of bias. For one study the reported confidence intervals suggested 
relatively precise effect estimates,27 but the intervention in the second study had no effect 
on CLABSI.31 The third study24 had a high risk of bias and the fourth study33 had an unclear 
risk of bias. Thus, the body of evidence of multimodal IPC interventions for CLABSI incidence 
rates per 1,000 patient or line days may be considered low quality.  
 
In the IPC care bundles group of interventions, two studies42,43/44 reported CLABSI rates per 
1,000 line days. These studies used an ITS design and received a high risk of bias, so this 
body of evidence may also be considered low quality. 
 
Discussion 
This review of the effectiveness of IPC interventions was undertaken to inform the 
development of international guidance on national IPC programmes. Although a high level 
of heterogeneity of interventions was observed, it was possible to identify four categories of 
IPC intervention: multimodal IPC interventions (n = 18 studies)24–41; IPC care bundles (n = 3 
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studies)42–45; IPC policies (n = 6 studies)46–51; and IPC surveillance, monitoring, and feedback 
(n = 2 studies).52,53 
 
Evidence of effectiveness of IPC interventions, based on international, national, state or 
collaborative guidelines and implemented countrywide, region wide or across countries, 
regions or collaborations, for guideline development was limited to a small number of 
individual studies. Of the 29 included studies, high quality evidence with a low risk of bias 
was provided by four studies of multimodal interventions, 25,27,28,31 and one study of a 
monitoring, surveillance, and feedback intervention.
52
 In addition, a moderate level of 
evidence was provided by two studies of multimodal interventions29,33 and a study of 
monitoring, surveillance and feedback interventions53 with an unclear risk of bias. Another 
study of monitoring, surveillance and feedback interventions52 had both primary and 
secondary outcomes. It had a low risk of bias for the primary outcome and a moderate risk 
of bias for the secondary outcome. 
 
Multimodal interventions were supported by the highest number of studies, with the 
majority demonstrating effectiveness. However, they evaluated IPC components collectively 
while the individual impact of each component was not identifiable, nor was which 
interventions collectively had the best impact on outcome, as no two studies included the 
same combination of interventions. This is a recurrent theme in the IPC literature, both at 
an organisational level and wider.8.9  
 
Surveillance with active feedback tends to report positive effects, even when it is a single 
intervention. Effective studies used national HH data for feedback at an individual level to 
drive behaviour change52 and national infection rates as a benchmarking tool to drive 
comparisons and improvement across hospitals.53 Additional studies reporting a positive 
impact of national surveillance exist outside this review but were not included as they did 
not meet our inclusion criteria mainly linked to the absence of control comparators. Indeed, 
following introduction of national surveillance at one point in time in all hospitals, the first 
year is normally used as a proxy baseline and temporal trends are reported thereafter.56–60 
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Nonetheless there are a number of papers in the IPC literature reporting observational 
evidence that when national HAI surveillance is introduced there is a significant reduction in 
HAI seen by year 3 of the programme. This impact has been observed in Germany with SSI 
and MRSA,59,60  France with SSI and MDRB,56,57,61,62 Italy with SSI,63 Finland with CDI,60 and 
the USA with overall HAI.64 
 
The review identified some evidence, although subject to bias and low quality, for two other 
interventions, namely, care bundles and policies, including development of guidelines 
accompanied by related healthcare workers’ education and training. Absence of evidence 
meeting the inclusion criteria does not of course infer absence of effect, or importance of 
the other key interventions required for national level IPC programmes. No study was found 
to evaluate the effectiveness of establishing a comprehensive national IPC programme to 
reduce HAI and AMR. However, the experts evaluating the evidence strongly affirmed that 
each country should have a stand-along, active national IPC programme. 
 
The strengths of this review are that it was conducted in a systematic and rigorous manner 
and that to the authors’ knowledge this is the first systematic review evaluating IPC 
interventions to guide the implementation of effective national IPC programmes. The 
comprehensive search comprised an extensive range of appropriate index terms and free 
text words and spanned four major databases and one specialist repository over a wide time 
period (January 1, 2000 to April 19, 2017). Citation searches of included studies were also 
conducted. Other methodological strengths include the focus on studies meeting the EPOC 
design criteria13-15 and the use of design-specific quality assessment tools recommended by 
Cochrane and EPOC.16-23 However, despite aiming to be inclusive of all countries and having 
the resources to translate studies in several languages, the focus on studies meeting the 
EPOC criteria resulted in studies from only seven high-income countries and one upper-
middle income country being included. This emphasises the need to build research 
capability and capacity specifically to enhance the evidence base from a wider range of 
countries, and in particular from low- / middle-income countries.  
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The review describes a lack of high quality studies using comparable primary outcomes. This 
limits the development of evidence-based international guidance to shape policy and 
practice. However, clear recommendations can be made for improvement in future research 
design for such studies to develop a viable evidence base. Exclusion of many studies was 
due to their study design. The majority were cohort studies that did not meet the EPOC 
study design criteria. However, these studies could still provide some important and 
valuable evidence in the absence of studies with more rigorous study designs and can be 
taken into account when guidelines are being developed. As a consequence, there is a need 
for improved research design with CRT, better designed epidemiology studies including 
rigorous time series analysis,14 and the consistent use of core outcomes to inform the future 
evidence base for IPC. A stepped-wedge design would be ideal as it would potentially allow 
the evaluation of the effect of different interventions introduced in a step-wise manner in 
different sites. Furthermore, the use of consistent measurements for specific outcomes 
according to standardised definitions is crucial in order to make meta-analysis feasible and 
allow the assessment of impact from the body of the evidence of studies with the same 
outcome. In addition, it is important to measure, both outcomes and processes, in particular 
if an experimental design is not possible. This is crucial to demonstrate that behavioural and 
practice changes have occurred and can help relate the changes to the intervention in non-
controlled and non-randomized studies.65 It is recognised that such experimental 
approaches are challenging as national policy initiatives for IPC interventions are often 
implemented at pace, not designed with evaluation built in from the outset, and evaluated 
retrospectively, if at all.66,67 
 
In addition to the lack of studies meeting the EPOC design criteria, there were key omissions 
relating to the detail of reporting about the intervention content, how it was implemented, 
and its hypothesised mechanisms of action. These must be addressed in future IPC research 
as they are crucial for replicability and dissemination. The studies that evaluated the effect 
of a multimodal IPC intervention, for example, tended to report positive effects from the 
intervention whereas challenges encountered and related solutions, if any, were neglected. 
Furthermore, the relative contribution of individual elements was usually not identifiable, 
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nor was any sense of the impact of particular combinations of elements upon outcome. This 
is a recurrent theme in the IPC literature which seriously limits our ability to build 
cumulative and transferable evidence relating to intervention elements.8,9 In addition, 
studies tended not to have specified any theoretical underpinning. The use of theory 
provides a hypothesized mechanism of change. This can provide a rationale for the delivery 
of specific elements in particular combinations in specific contexts and can improve the 
coherence of complex interventions and limit the inclusion of extraneous intervention 
components.  
 
These key omissions can be remedied by using behavioural theories and tools such as the 
Theory Coding Scheme68 and the Behaviour Change Technique Taxonomy,69 wider 
approaches from implementation science, and quality improvement methodologies. 
Together, these inform intervention development, intervention evaluation and foster 
reporting of key outcome measures. Culture and social context are also important in order 
to understand the success or failure of IPC interventions.70 These should also be taken into 
account to better understand the implementation of IPC strategies.71 This is particularly true 
with regard to the dearth of research in low-income countries. Implementing effective 
interventions within the developed world alone will not help to contain HAI and AMR in the 
global context. Finally, studies need to be reported in such a way that they can be replicated 
in different contexts. There is a growing body of literature to guide authors72–74 that could 
strengthen reporting practice. 
 
In conclusion, the best available evidence to inform international recommendations about 
effective IPC programmes comes from individual studies on IPC multimodal interventions 
and studies on surveillance, monitoring, and feedback. We call for urgent improvements in 
the use of more robust study designs in IPC research and research investigating the cultural 
and international relevance of IPC interventions. This review has made a major contribution 
to illustrate the state of current evidence in relation to national and sub-national IPC 
interventions. The findings provide direction for international guidance which will shape 
global action to prevent and control HAI and contain AMR. 
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Figure 1 Flow diagram of study selection  
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Table 1 Study characteristics and summary assessment of risk of bias 
Authors Study 
design  
Intervention content Intervention guidelines Intervention implemented Sample size  Summary 
assessment of 
risk of bias 
National multimodal infection prevention and control interventions 
  
CLABSI 
 
Bion et al 
(2013)23  
 
NRT Care bundle, cultural change, surveillance, 
training, ad hoc support and guidance, 
teamwork and communication, and executive 
support 
“Matching Michigan”  National 
Patient Safety Agency central line 
CRBSI  multimodal programme 
All 139 acute hospitals in 
England, UK 
223 ICU 
438,887 patient days (adult 
404,252; paediatric 34,635) 
High risk 
Marsteller et 
al (2012)26 
 
CRT Care bundle, cultural change, training, 
teamwork and communication, executive 
support, checklist, learning from incidents, and 
identified lead 
Keystone ICU and Comprehensive 
Unit-based Safety Program 
Adventist Health and Adventist 
Health System in West and 
Midwest and Southeast regions of 
USA 
35 hospitals from 12 states 
45 ICU 
Low risk 
Hansen et al 
(2014)32 
 
ITS Surveillance, care bundle, teaching materials, 
train the trainers, and posters/campaign 
materials 
Krankenhaus Surveillance System 
(KISS) CLABSI Programme 
All ICU (107) in Germany with 
CLABSI rates equal to or greater 
than the national average 
32 ICU intervention group 
344 ICU control groups 
266,471 central line-days 
intervention group 
Unclear risk 
Herzer et al 
(2014)35 
USA 
Economic 
evaluation 
Care bundle, cultural change, and performance 
feedback 
On the CUSP: stop BSI national 
collaborative 
1200 US hospitals Hospital setting 
Adult ICU 
NA 
 
MRSA 
 
Jain et al 
(2011)31 
 
ITS Care bundle, cultural change, training, train the 
trainers, and funding 
Veterans Health Administration 
National MRSA Prevention 
Initiative 
All 153 Veterans Hospitals USA 153 hospitals 
624 acute care units. 
1,934,598 admissions. 
High risk 
Newitt et al 
(2015)33 
 
ITS Care bundle, provision of ABHR, performance 
feedback, posters/campaign materials, and 
policy review 
National and regional HAI 
interventions  
Areas Health Services (NHS 
Trusts) East Midland Region, 
England, UK 
8 Area Health Services. High risk 
 
Hand hygiene 
 
Ho et al 
(2012)24 
 
CRT Training, provision of ABHR, train the 
trainers, performance feedback, and 
posters/campaign materials. Intervention arm 1 
- slightly powdered gloves, intervention arm 2 
- powderless gloves 
World Health Organization 
multimodal hand hygiene strategy 
Care and attention nursing homes 
in Hong Kong 
18 LTCFs  
11,669 HH opportunities 
High risk HH 
compliance 
Low risk 
respiratory 
outbreaks and 
MRSA infections 
Stevenson et 
al (2014)28 
 
CRT Training, provision of ABHR, training 
materials, train the trainers, performance 
feedback, and posters/campaign materials 
Healthcare Infection Control 
Practices Advisory Committee and 
the ICPAC/SHEA/APIC/IDSA 
guidelines 
Community hospitals in Idaho 
and Utah, USA 
10 hospitals 
4,527 HH opportunities 
Unclear risk  
Yeung et al 
(2011)29 
CRT Training, provision of ABHR, and 
posters/campaign materials. 
World Health Organization hand 
hygiene guidelines 
Community-based , private or 
semiprivate residential long-term 
6 LTCFs. 
3,300 HH opportunities. 
High risk  
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Authors Study 
design  
Intervention content Intervention guidelines Intervention implemented Sample size  Summary 
assessment of 
risk of bias 
 care facilities in different regions 
of Hong Kong 
Graves et al 
(2016)34 
 
Economic 
evaluation 
Cultural change, surveillance, training, 
teaching materials, and train the trainers 
Australian National Hand Hygiene 
Initiative 
All states and territories in 
Australia 
50 largest acute public hospitals 
representative of 8 states/ territories. 
1,294,656 admissions to 24,482 beds  
NA 
McLaws et al 
(2009)38 
 
CBA Provision of ABHR, posters/campaign 
materials, and identified lead 
State wide Clean hands saves lives 
campaign 
All public hospitals in New South 
Wales, Australia 
Hospital setting 
10/11 Area Health Services 
High risk 
 
Other  
 
Makris et al 
(2000)25 
 
CRT HAI teaching materials, visits to sites, and 
policy review 
Medisys Infection Control 
Surveillance Programme 
mandated by the Health Care 
Finance Administration 
LTCFs in New Jersey and 
Delaware, USA 
8 LTCFs 
900 beds 
High risk 
Mody et al 
(2015)27 
 
CRT Care bundle, surveillance, and training Centers for Medicare & Medicaid 
Targeted Infection Program 
Community-based LTCFs in 
Southeast Michigan, USA 
12 LTCFs 
418 patients 
34,174 device days 
Low risk 
Cavalcanti et 
al (2016)30 
 
CRT Surveillance, training, ad hoc support and 
guidance, teamwork and communication, 
performance feedback, visit to sites, and check 
list 
CDC/National Healthcare Safety 
Network  recommendations and 
standards 
ICU from all Brazilian regions 118 ICU (6,761 patients). 
59 intervention ICU (3,327 
patients). 
59 control ICU (3,434 patients). 
Low risk 
Slayton et al 
(2015)36 
 
Economic 
evaluation 
CDI care bundle and surveillance Society for Healthcare 
Epidemiology of America and the 
Infectious Disease Society of 
America CDI  guidelines  
USA hospitals Hospital setting 
Medicare patients aged >65 years 
NA 
Lipitz-
Snyderman et 
al (2011)37 
 
CBA CRBSI and VAP care bundle, cultural change, 
training, and teamwork and communication 
Michigan Health n and Hospital 
Association Keystone ICU project  
All 132 Michigan hospitals, USA 95 hospitals intervention group. 
1,331,484 hospital admissions for 
adults aged 65 or older. 
364 hospitals from 11 States control 
group. 
1,091,547 hospital admissions. 
High risk  
Reames et al 
(2015)39 
 
CBA SSI care bundle, cultural change, training, 
teamwork and communication, executive 
support, checklist, and learning from incidents. 
Keystone Surgery Program 101 hospitals in Michigan, USA 29 hospitals 
64,891 patients 
High risk  
 
Wirtschafter et 
al (2011)40 
 
CBA Nosocomial infection care bundle, training, 
and teaching materials 
California Perinatal Quality Care 
Collaborative program 
Hospitals who are members of the 
California Perinatal Quality Care 
Collaborative USA 
54 NICU 
7,733 very low birth weight infants 
in 27 participating NICU and 4,512 
very low birth weight infants in 27 
non-participating NICU 
High risk 
National infection prevention and control care bundles 
Bundy et al ITS Central line maintenance care bundle CDC recommendations and Multicentre collaboration operated 32 paediatric haematology/ oncology High risk 
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Authors Study 
design  
Intervention content Intervention guidelines Intervention implemented Sample size  Summary 
assessment of 
risk of bias 
(2014)41 
 
standards by the Children’s Hospital 
Association. Healthcare centres 
across the USA participated 
inpatient units 
Miller et al 
(2010 & 
2011)42,43 
 
ITS Insertion and maintenance CVC care bundles CDC Insertion and Maintenance 
Care Bundle 
65 PICU in the National 
Association of Children’s 
Hospitals and Related 
Institutions, USA 
29 paediatric ICU 
501,911 central line-days 
  
High risk 
Schweizer et 
al (2015)44 
 
ITS SSI care bundle 
S. aureus screening, decolonisation, and 
antibiotic prophylaxis 
American Society of Heath-System 
Pharmacists guidelines and CDC 
guidelines 
The Hospital Corporation of 
American affiliated hospitals 
20 hospitals in 9 States 
42,534 surgical operations 
High risk 
National infection prevention and control policies 
Lee et al 
(2012)45 
 
ITS Non-payments for preventable HAI Centers for Medicare and 
Medicaid Services Non-Payment 
for preventable conditions 
All Medicare hospitals USA but 
only 1166 acute hospitals eligible 
to participate inclusion in study as 
members of the National Patient 
Safety Network performing 
surveillance of HAI  
Catheter-associated BSI: 398 
hospitals and 4,932,056 device days 
CAUTI: 543 hospitals and 
3,244,462 device days 
VAP: 548 hospitals and 2,050,996 
device days 
High risk 
Schuller et al 
(2014)46 
 
ITS Non-payment policy on CAUTI Medicare non-payment policy for 
CAUTI 
All Medicare hospitals, USA Hospitals in the Nationwide 
Inpatient Sample 
1050 hospitals 
8,000,000 discharges 
High risk 
Schwaber et al 
(2011)47 
 
ITS Mandatory public reporting and isolation of 
carbapenem-resistant enterobacteriaceae 
carriers. Task force visited sites, supervised 
adherence to guidelines, and provided 
feedback on performance to hospital directors 
CDC guidelines All acute hospitals in Israel 13,040 beds 
27 acute care hospitals 
High risk 
Marsteller et 
al (2014)48 
CBA State laws mandating public reporting of 
CLABSI rates 
State mandatory reporting of 
CLABSI using CDC definitions 
44 states, Washington DC, and 
Puerto Rico, USA 
Mandatory reporting in 30/47 states 
36% of all  hospital participated 
771 hospitals 
High risk 
Schmier et al 
(2016)49 
 
Economic 
evaluation 
Health care personnel hand washes and rubs, 
surgical hand scrubs and rubs, and patient 
preoperative and preinjection skin preparations 
Hospital costs of HAI if 
antiseptics were removed from 
guidance 
Hospitals in the USA US hospitals 
 
NA 
Robotham et 
al (2016)50 
 
Economic 
evaluation 
Screening and intervention strategies 
including: 
(1) no screening; (2) screening of all admissions; 
(3) screening of admissions to high-risk 
specialties; (4) checklist-activated screening;  
(5) screening of admissions to high-risk 
specialties plus checklist-activated screening of 
other admissions; (6) screening of all admissions 
National universal mandatory 
screening for MRSA 
All hospitals in England, UK English hospitals – acute, teaching 
and specialist. 
NA 
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Authors Study 
design  
Intervention content Intervention guidelines Intervention implemented Sample size  Summary 
assessment of 
risk of bias 
plus pre-emptive isolation of individuals known 
to be previously MRSA positive  
National infection prevention and control surveillance, monitoring, and feedback 
Fuller et al 
(2012)51 
 
CRT Observation, feedback, personalised action 
planning 
National “cleanyourhands” 
campaign  
All hospitals across England and 
Wales, UK 
16 hospitals 
16 ITU 
44 wards 
 
Low risk HH 
compliance 
Unclear risk 
consumption 
ABHR 
McKinley et 
al (2003)52 
CRT CDC surveillance and risk-adjusted feedback on 
infection rates (with and without national 
comparative data) 
National Nosocomial Infections 
Study System 
Network of Veterans Affairs 
hospitals with nosocomial 
infections above the 90th 
percentile (62) 
 8 hospitals in 3 different states Unclear risk 
 
ABHR – Alcohol-Based Hand Rub 
BSI – Blood Stream Infection  
CAUTI – Catheter Associated Urinary Tract Infection 
CBA – Controlled Before and After 
CDC = Centers for Disease Control and Prevention 
CDI – Clostridium difficile Infection 
CLABSI – Central-Line Associated Blood Stream Infection 
CRBSI – Catheter-Related Blood Stream Infection  
CRT – Cluster Randomised Trial 
HAI – Healthcare Associated Infection 
HH – Hand Hygiene 
ICU – Intensive Care Unit 
ITS – Interrupted Time Series 
LTCF – Long-Term Care Facility 
MRSA – Meticillin Resistant Staphylococcus aureus  
NICU – Neonatal Intensive Care Unit 
NA – Not Applicable 
NRT – Non-Randomised Trial 
PICU – Paediatric Intensive Care Unit 
S. aureus – Staphylococcus aureus 
SSI – Surgical Site Infection 
VAP – Ventilator Associated Pneumonia 
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Table 2 Study outcomes 
Study  Outcomes 
National multimodal infection prevention and control interventions 
  
CLABSI 
 
Bion et al 
(2013)23  
CVC-BSI/1,000 CVC-patient days decreased from 3·7 to 1·48 (p < 0·0001) for adult ICU. CVC-BSI/1,000 CVC-patient 
days decreased from 5·65 to 2·89 for paediatric ICU (p = 0·625). 
Marsteller et 
al (2012)26 
Baseline rate of CLABSI/1,000 CL-days was 4.48 and 2.71 for the intervention and control groups, respectively (p = .28). 
The CLABSI rate declined to 1.33 in the intervention group compared to 2.16 in the control group (adjusted incidence 
rate ratio 0.19; p = .003; 95% CI 0.06-0.57). The intervention group sustained CLABSI rates <1/1,000 CL-days at 19 
months (an 81% reduction). The control group also reduced CLABSI rates to <1/1,000 CL-days (a 69% reduction) at 12 
months. 
Hansen et al 
(2014)32 
 
At baseline, the CLABSI rate was 2.29 per 1,000 CL-days and this decreased significantly to 1.64 per 1000 CL-days in 
the follow-up period. Compared with baseline, the RR for CLABSI was 0.88 (95% CI 0.70-1.11) for the intervention 
period and 0.72 (95% CI 0.58-0.88) for the follow-up period. 
Herzer et al 
(2014)35 
Cost-effectiveness demonstrated. The quality improvement programme prevents 42 CLABSIs per 1,000 patients and 
averts 6 deaths per 1,000 patients at no additional cost compared to current practice. 
 
MRSA 
 
Jain et al 
(2011)31 
MRSA infections decreased: ICU from 1·64 to 0·62 infections per 1,000 patient-days (p < 0·001) and non-ICU from 
0·47 to 0·26 per 1,000 patient-days (p < 0·001). 
Newitt et al 
(2015)33 
7 of 8 Area Health Services had a significant decreasing trend for MRSA incidence rates per 100,000 bed-days during 
implementation and maintained in the post intervention phase (p < 0·001). Increasing trends in 4 hospital groups for 
MSSA. 
 
Hand hygiene 
 
Ho et al 
(2012)24 
HH compliance increased from 27·0% to 60·6% and from 22·2% to 48·6% in intervention arms 1 and 2, respectively, 
compared to controls at 21·6% compliance (both p < 0·001).  Respiratory outbreaks (IRR 0·12; 95% CI 0·01 to 0·93; p = 
0·04) and MRSA infections requiring hospital admission (IRR 0·61; 95% CI 0·38 to 0·97; p = 0·04) were reduced.   
Stevenson et 
al (2014)28 
The estimated average absolute change in “complete HH compliance” was 20·1% in intervention hospitals vs -3·1% in 
control hospitals (p = 0·001).  The estimated average absolute change in “any HH compliance” was 28.4% in intervention 
hospitals compared to 0.7% in control hospitals (p = 0.010).   
Yeung et al 
(2011)29 
ABHR HH compliance improved from 5% to 15·9% (p = 0·001) and total HH adherence increased from 25·8% to 33·3% 
(p = 0·01); the control group showed no significant change. Incidence of infections decreased from 1·42 to 0·65 cases per 
1,000 resident-days (p = 0·002). In the control group, it increased from 0·49 to 1·05 cases per 1,000 resident-days (p = 
0·004).   
Graves et al 
(2016)34 
Total annual costs increased by $2,851,475 for a return of 96 years of life giving an ICER of $29,700 per life year gained. 
Probabilistic sensitivity analysis revealed a 100% chance the initiative was cost effective in the Australian Capital Territory 
and Queensland, with ICERs of $1,030 and $8,988, respectively. There was an 81% chance it was cost effective in New 
South Wales with an ICER of $33,353, a 26% chance for South Australia with an ICER of $64,729 and a 1% chance for 
Tasmania and Western Australia.  
McLaws et al 
(2009)38 
25% reduction in MRSA non-ICU sterile site infections, from 0·60 to 0·45/10,000 bed-days (p = 0·027), and a 16% 
reduction in ICU non-sterile site infections, from 36·4 to 30·4/10,000 bed-days (p = 0·037). Infection rates in ICU sterile 
sites (5·28 vs 4·80/10,000 bed-days, p = 0·664) and non-ICU non-sterile sites (5·92 vs 5·66/10,000 bed-days, p = 0·207) 
remained stable. 
 
Other  
 
Makris et al 
(2000)25 
Outcomes infections per 1,000 patient days. No significant difference between treatment vs controls in HAI (p = 0·19).  
No significant difference for types of HAI (p = 0·06 to p = 0·81). 
Mody et al 
(2015)27 
Risk of CAUTI was significantly lower in the intervention group vs the control group (hazard ratio 0·54 (95% CI 0·3 to 
0·97), p = 0·04). 23% reduction in multi-drug resistant organism prevalence density rate (rate ratio 0·77 (95% CI 0·62 to 
0·94, p = 0·01). 
Cavalcanti et 
al (2016)30 
 
No significant difference in the intervention and control group for CLABSI/1,000 patient days: RR 1·03 (95% CI 0·73 to 
1·45, p = 0·88) nor for VAP/1,000 patient days:  RR 1·04 (95% CI 0·68 to 1.58, p = 0·87). 
Slayton et al 
(2015)36 
CDI prevention is cost saving. Estimated that 509,000 CDI cases and 82,000 CDI-attributable deaths would be prevented 
over a 5-year time horizon. Nationally, the cost savings across all hospitalisations would be $2.5 billion. 
Lipitz-
Snyderman et 
al (2011)37 
Reductions in mortality were significantly greater for the study group than for the comparison group during post-
implementation months 1 to 12 (OR 0·83, 95% CI 0.79 to 0.87 vs OR 0·88, 95% CI 0.85 to 0.90, p = 0·041) and 13 to 22 
(0·76, 95% CI 0.72 to 0.81 vs 0.84, 95% CI 0.81 to 0.86, p = 0·007). Length of stay did not differ between groups (p = 
0·560). 
Reames et al 
(2015)39 
No improvements in surgical outcomes during the study period. Adjusted rates of superficial SSI were 3·2% before vs 
3·2% after (p = 0·91) and adjusted rates of 30-day mortality were 2·1% before vs 1·9% after (p = 0·32). 
Wirtschafter et 
al (2011)40 
For the entire cohort, the rate of nosocomial infection decreased from 16·9% in 2002 to 14·5% in 2006 (p = 0·02). For 
infants admitted to NICU participating in at least one quality improvement event, there was an associated decreased risk 
of nosocomial infection (OR 0·81, 95% CI 0·68 to 0·96) compared with those admitted to nonparticipating hospitals. 
National infection prevention and control care bundles 
Bundy et al 
(2014)41 
Significantly lower CLABSI 28% reduction in the rate. Odds of no CLABSI in a given unit in a given month during the 
intervention period was 2·59 times the odds during the pre-intervention period comparing unit with similar central line 
day (p = 0·001). Changes in self-reported central line care bundle compliance were not statistically associated with 
changes in CLABSI rates.   
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Study  Outcomes 
Miller et al 
(2010 & 
2011)42,43 
Paediatric ICU CLABSI rate decreased 56% over 36 months from 5·2 to 2·3 CLABSI per 1,000 line-days (rate ratio 0·44, 
95% CI 0·37 to 0·53, p < 0·0001). Increase in insertion and maintenance bundle compliance rates over time period, Oct 
2006-Sept 2009 (no data provided) 
Schweizer et 
al (2015)44 
Reduced mean SSI rate 36 vs 21 per 10,000 operations, difference -15 (95% CI -35 to -2; rate ratio 0·58, 95% CI 0·37 to 
0·92). Bundle adherence remained constant at 83% (full adherence, 39%; partial adherence, 44%). The complex S aureus 
SSI rates decreased significantly (rate ratio 0·26, 95% CI 0·10 to 0·69), but rates did not decrease significantly in the 
partially adherent or non-adherent group (rate ratio 0·80; 95% CI 0·49 to 1·31).   
National infection prevention and control policies 
Lee et al 
(2012)45 
Outcomes were defined as the quarterly rate of each HAI per 1,000 device-days exposed. No impact of policy 
implementation on catheter-associated BSI (IRR 1·00, p = 0·97), CAUTI (IRR 1·03, p = 0·08), or VAP (IRR 0·99, p = 
0·52). 
Schuller et al 
(2014)46 
Outcome CAUTIs per 1,000 patient discharges. No significant rate of change with CAUTI after the policy change (p = 
0·3577). 
Schwaber et al 
(2011)47 
Reduction in the incidence of carbapenem-resistant enterobacteriaceae 55·5 vs 11·7 cases per 100,000 patient-days (p < 
0·001). Correlation between compliance with isolation guidelines and success in containment of transmission (p = 0·02). 
Compliance neutralised the effect of carrier prevalence on new incidence (p = 0·03). 
Marsteller et 
al (2014)48 
All groups had a reduction in CLABSI rates. Groups with new mandates had greater reduction in the first 6 months 
(voluntary: IRR = 0·73, 95% CI 0·56 to 0·94; older mandates: IRR = 0·83, 95% CI 0·70 to 0·99). Trend toward greater 
reduction in CLABSI after 1-year of programme implementation (new mandate: IRR 0·56, 95% CI 0·31 to 1·01; older 
mandate: IRR 0·83, 95% CI 0·68 to 1·01). 
Schmier et al 
(2016)49 
Low- and high-end estimates of national, annual HAIs in hospitals avoided through use of health care antiseptics are 12,100 
and 223,000, respectively, with associated hospital costs avoided of US$142 million and US$4.25 billion, respectively. 
Robotham et 
al (2016)50 
Screening all admissions was unlikely to be cost effective. Switching from screening all admissions to only high-risk 
specialty admissions was likely to represent better resource use with a mean reduction in total costs per year (not 
considering uncertainty) of £2·7 million per acute hospital, £2·9 million per teaching, and £474,000 per specialist hospital 
for a minimum rise in infections (about one infection per year per hospital). 
National infection prevention and control surveillance, monitoring, and feedback 
Fuller et al 
(2012)51 
Significant sustained improvement in HH compliance on intention-to-treat for ICU OR 1·44 (95% CI 1·18 to 1·76) p < 
0·001 and per-protocol analysis for acute care of the elderly ore medical wards (OR 1·.67, 95% CI 1·28 to 2·22, p < 
0·001) and ICU (OR 2·09, 95% CI 1·55 to 2·81, p < 0·001). Absolute difference in HH compliance 13% to18% on ICU, 
and 10% to 13% on acute care of the elderly or medical wards. Sustained effect. In the intention-to-treat analysis there 
was no evidence of a rise in ABHR procurement with the estimated relative change (95%CI) post-randomisation of 1.064 
(0.933 to 1.214); p = 0.4 in ICU and 1.027 (0.919–1.148); p =0.6 in ACE wards. Per-protocol analysis showed no increase 
in ABHR procurement for the wards with the estimated relative change post implementation being 1.183 (0.989 to 1.416) 
for acute care of the elderly or medical wards and 1.098 (0.904 to 1.333) for ICU. 
McKinley et al 
(2003)52 
A significant difference between the control and experimental group for CAUTI (p = 0·012), CLABSI (p = 0·006), VAP 
(p = 0·0025), and overall device-associated infection (p < 0·001). 
 
ABHR – Alcohol-Based Hand Rub 
CDI – Clostridium difficile Infection 
CVC – Central Venous Catheter 
BSI – Blood Stream Infection  
CAUTI – Catheter Associated Urinary Tract Infection 
CI – Confidence Interval  
CL – Central Line 
CLABSI – Central-Line Associated Blood Stream Infection 
HAI – Healthcare Associated Infection 
HH – Hand Hygiene 
ICER – Incremental Cost-Effectiveness Ratio 
ICU – Intensive Care Unit 
IRR – Incidence Rate Ratio 
MRSA – Meticillin Resistant Staphylococcus aureus  
MSSA – Meticillin Sensitive Staphylococcus aureus 
NICU – Neonatal Intensive Care Unit 
OR – Odds Ratio 
RR – Relative Risk 
S. aureus – Staphylococcus aureus 
SSI – Surgical Site Infection 
VAP – Ventilator Associated Pneumonia 
 
